《异动股》远大医药(00512.HK)整固後回升13%至九个月高成交增
远大医药(00512.HK)继昨天反覆整固後,今天股价创九个月高,最高见7.73元,现造7.7元,回升13%,成交增至2,392万股,已创逾两个月高,涉资1.8亿元。
远大日前公布,全资附属Grand Medical正在开发用於重症感染领域的全球创新药物STC3141,日前在比利时顺利完成用於治疗重症新冠病患者的IIa期临床试验首四例患者入组,并顺利完成连续给药。今次入组给药旨在研究和评估药物在治疗因感染型冠病毒所引发的病毒性肺炎重症患者中安全性、有效性及最佳给药策略,进一步扩大产品适用范围,积累更多资料综合评估後期临床试验的风险和效益,以加快产品的全球开发进程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.